Introduction: Cervical cancer is the second most prevalent cancer among women worldwide. High-Risk Human Papilloma virus (hr-HPV) is an established cause of cervical cancer and precancerous lesion. Studies have shown the relationship between the HPV-DNA test with cervical precancerous and cancerous lesion in diagnosing cervical cancer. This study aimed to correlate HPV-DNA test with both cytology and histology.
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Results
The HC-2 was carried out on all 99 histologically positive cases. Among the 99 cases, 28(28.28%) cases were positive and the rest 71(71.72%) cases were negative by HC-2 assay (Table-I ). The comparison of sensitivity and accuracy of Pap smear cytology and HC-2 are revealed in Table- IV. Sensitivities of Pap smear cytology and HC-2 were 49.5% and 28.3% respectively. The accuracy of smear cytology and HC-2 were 66.44% and 58.2% respectively. As the number of true negative samples is zero, specificity could not be estimated. and 92% respectively which are almost similar to the present study. However, a significant relationship was observed between HC-2 and cytological diagnosis (P<0.005).
The comparative analysis of the sensitivity and accuracy of Pap smear cytology and HC-2 was carried out in this study and Pap smear showed better sensitivity than HC-2. The sensitivity and accuracy of Pap smear cytology are 49.5% and 66.4% respectively. While those of HC-2 assay were 28.3% and 58.2% respectively. In this study, the number of true negative samples is zero, because all 99 samples were obtained from histologically proven cases of cervical cancer and precancer. Due to this fact specificity of Pap smear and HC-2 could not be estimated.
Conclusion
In this study, although the sensitivity of HC-2 was not that high, significant correlations have been observed between HC-2 and histological findings; and HC-2 and Pap smear. Stringent DNA sample collection and storage is necessary for a better result. However HC-2 assay can be a useful adjunct with Pap smear during primary screening and follow up in resource-rich settings.
